AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04506125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Haemoglobine 7.5g/dL
Description: transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
Study NCT06635460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social media-based patient monitoring
Description: Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
Study NCT06636058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vCare Intervention (6-month active treatment followed by 6-month maintenance)
Description: During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks.
Study NCT06636058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vCare Intervention (active treatment after 6 months)
Description: During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
Study NCT06106477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM).
Study NCT05093517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
Study NCT05093517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous injection
Description: Placebo for REMD-477 to which subjects will be randomized 1:2.
Study NCT05290883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel yoghurt drink containing Polar Lipids
Description: Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
Study NCT05106140 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.
Study NCT05037942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 40% limb occlusion pressure
Description: A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
Study NCT05037942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 80% limb occlusion pressure
Description: A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
Study NCT04854616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoSTED Intervention
Description: Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
Study NCT05143437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love Together Parent Together
Description: A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
Study NCT04895228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection
Description: triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
Study NCT04895228 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: injection
Description: triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
Study NCT05263531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
Study NCT05263531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
Study NCT06266923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH6516 tablets
Description: SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
Study NCT05106140 — intervention group
Intervention type: DEVICE
Intervention: Kinarm Robotic Exoskeleton Assessment
Description: The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours.
Study NCT05113901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
Study NCT05113901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
Study NCT06539273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exosome Complex, RNA
Description: A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
Study NCT05351073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBO
Description: Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
Study NCT05124431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
Study NCT05124431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 5mg po，qd
Study NCT06242873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with/without TSCS
Description: To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
Study NCT06242873 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Gait training with/without TSCS
Description: To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
Study NCT05726773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Therapy
Description: In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
Study NCT05726773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
Study NCT05726773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
Study NCT05154994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT05154994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05006781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration
Study NCT05006781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleassistance
Description: Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Support from a physiotherapist (if needed)
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telepsycology
Description: Psychological support (if necessary)
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life
Description: Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biochemistry evaluation
Description: Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biochemistry evaluation
Description: Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: 6-minute-walking test, IMC, NYHA class, Ejection fraction
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: 6-minute-walking test, IMC, NYHA class, Ejection fraction
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: State of health of the patient
Description: Severity Index and Comordbidity index
Study NCT05633784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State of health of the patient
Description: Severity Index and Comordbidity index
Study NCT05219201 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).
Study NCT05219201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).
Study NCT05106140 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
Study NCT05404529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study NCT04675073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia substrate-based radiofrequency ablation
Description: The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
Study NCT05408130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device
Description: All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
Study NCT05408130 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device
Description: In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
Study NCT05219773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NuvoAir Air Next spirometer
Description: * The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey.
Study NCT00610051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprostadil
Description: central venous access continuous delivery with 500mcg/48 hours in active arm
Study NCT00610051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil
Description: central venous access continuous delivery with 500mcg/48 hours in active arm
Study NCT06175494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Description: boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Study NCT06175494 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Description: boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Study NCT06175494 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: boost with saline
Study NCT05792553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonded tongue tamers
Description: Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
Study NCT05792553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized bonded spurs
Description: Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
Study NCT04352036 — intervention group
Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study NCT05792553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional fixed palatal spurs
Description: conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
Study NCT05668715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
Study NCT05668715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
Study NCT06533124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.
Description: In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
Study NCT04741139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Diphenhydramine Only Product
Description: Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
Study NCT04901871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02 mg/kg, age<65
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
Study NCT04901871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.07 mg/kg, age<65
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
Study NCT04901871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12 mg/kg, age<65
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.